EGFR and non-small cell lung carcinoma: Comparable to EGFR mutated NSCLC, conversion from adenocarcinoma to SCLC has been documented in a patient progressing on alectinib [76], thus confirming that histology transformation represents an escape mechanism in molecularly defined subgroups of NSCLC patients receiving a targeted agent.